Oncomirs are microRNAs (miRNAs) that acts as oncogenes or tumor suppressor genes. Efficient identification of oncomirs remains a challenge. Here we report a novel, clinically-guided genetic screening approach for the identification of oncomirs, identifying mir-30d through this strategy. mir-30d regulates tumor cell proliferation, apoptosis, senescence, and migration. The chromosomal locus harboring mir-30d was amplified in >30% of multiple types of human solid tumors (n=1,283).
Introduction
Cancer is a genetic disease involving multistep changes in the genome (1) . Most studies to date have focused mainly on the role of protein-coding sequences in cancer. Although non-coding sequences constitute up to 98% of the human genome and have been implicated in tumorigenesis, our knowledge of the function of these genomic sequences in cancer is still limited (2) (3) (4) (5) (6) (7) . microRNAs (miRNAs) are noncoding RNAs about 22 nucleotides in length which regulate gene expression in a sequence-specific manner (2-4, 6, 8-13) . Increasing evidence indicates that miRNAs may play a critical role in cancer (14) (15) (16) (17) (18) (19) (20) (21) . miRNAs act as key regulators of various fundamental biological processes, many of which share common pathways with the development of cancer. In addition, it has been widely reported that miRNA expression is remarkably deregulated in cancer. Several miRNAs have already been shown to play a critical role in cancer. Referred to as "oncomirs", these miRNAs can act as either tumor suppressors or as oncogenes (4) . Current rapid advances in oligonucleotide/nanoparticle therapies create a realistic optimism for the establishment of miRNAs as a new and potent therapeutic target for cancer treatment (22) (23) (24) (25) . However, the efficient identification of oncomirs remains a challenge. Although both microarray based high throughput genomic/genetic profiling (3, 18, 19, 26) and whole genome-wide genetic screening (16, (27) (28) (29) (30) (31) have been successfully applied to the identification of oncomirs in human cancer, both approaches have limitations. Genome-wide screening is time and labor intensive, and most importantly, can produce artifacts. The profiling strategies cannot distinguish "causal" from "bystander" genetic events. In this study, we report a novel, clinically guided genetic screening approach to identify oncomirs involved human cancer. Based on this approach, one promising oncomir candidate, mir-30d, was successfully identified.
Materials and Methods
Patients and specimens-All frozen ovarian cancer specimens were collected at the University of Turin.
Detailed information is provided in Supporting Methods. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 4, 2011; DOI: 10.1158/0008-5472. CAN-11-2484 Cell lines and cell culture-Cancer cell lines 2008, OVCAR5, OVCAR10, OWA42, MDA-MB-231, T47D, HCT116, and BT549 were purchased from ATCC or DCTD Tumor/Cell Line Repository. Four independent immortalized human ovarian surface epithelial cell lines (IOSEs) were generously provided by Dr. Nelly Auersperg. All cancer cell lines were obtained directly from ATCC or DCTD that performs cell line characterizations and passaged in our laboratory for fewer than 6 months after receipt. The method of characterization used by ATCC or DCTD can be found in its website. Detailed information is provided in Supporting Methods.
Retroviral transductions-
The retrovirus-based human miRNA expression vector (pmiRvec) was purchased from GeneService (27) . Retroviral vectors containing human miRNAs were transfected into the packaging cell line PT67 (Clontech) using the FuGene6 Transfection Reagent (Roche). The growth media was changed 48 hrs post-transfection and the media containing retrovirus was collected 48 hrs later.
Human tumor cells were infected with retrovirus in the presence of 8 μg/ml of polybrene and selected using the antibiotic blasticidin (Invitrogen).
Transfection of miRNA mimic oligos and of miRZip miRNA inhibitors-Pre-miR miRNA precursors and control oligos were purchased from Ambion. miRZips lentiviral-based miRNA inhibition vectors and control vectors were purchased from System Biosciences. The effects of transfection or infection on endogenous mir-30d expression were examined by real-time RT-PCR ( Figure S1 ). Detailed information is provided in Supporting Methods.
RNA isolation and TaqMan miRNA assays-Total RNA was isolated from 100 to 500 mg of frozen tissue or 1 x 10 6 cultured cells using TRIzol reagent (Invitrogen). The expression of mature miRNAs was analyzed using the TaqMan miRNA Assay (Applied Biosystems). Detailed information is provided in Supporting Methods.
MTT proliferation assays, cell cycle assays, caspase-3 activity assays, Annexin-V apoptosis assays, ȕ-Gal senescence assays, and migration assays-Detailed information is provided in Supporting Methods. Western blots-Anti-total caspase-3 and anti-cleaved caspase-3 primary antibodies were purchased from Cell Signaling Technology. Detailed information is provided in Supporting Methods. Array-based comparative genomic hybridization (aCGH)-BAC clones included in the "1 Mb-array" platform have been previously described (32) . Detailed information is provided in Supporting Methods.
Generation of the in vivo
Analysis of DNA copy number profiling data sets-We examined whether mir-30d exhibits a high frequency of genomic amplification in a variety of human cancers by analyzing a panel of high resolution DNA copy number profiling data sets. These data sets consisted of 1,282 primary tumors representing nine human cancer types. Detailed information is provided in Supporting Methods.
Single-nucleotide polymorphism (SNP) arrays-A total of 192 established tumor cell lines were analyzed using the Affymetrix 500K SNP chip (Affymetrix) (data were collected by Joel Greshock and Barbara L. Weber at GlaxoSmithKline). Detailed information is provided in Supporting Methods.
SNP data analysis-All SNP chip images ('CEL files'), were extracted using Affymetrix Genotype software, and analyzed using the dChip software package. Detailed information is provided in Supporting Methods.
Tissue microarrays-Detailed information is provided in Supporting Methods. Bioinformatic analysis-mir-30d targets were predicted using TargetScan (33) . miRNA effects to the expression levels of protein-coding transcripts were identified by DIANA-mirExTra (34) .
Quantitative real time RT-PCR-Total RNA was reverse-transcribed using a High Capacity RNA-tocDNA Kit (Applied Biosystems) under conditions provided by the supplier. cDNA was quantified by RT-PCR on an ABI Prism 7900 Sequence Detection System (Applied Biosystems).
Statistical analysis-Statistical analysis was performed using the SPSS or SAS statistics software package. All results were expressed as mean ± SD, and p<0.05 was used for significance.
Results

A clinically guided genetic screening approach to identify oncomirs
We hypothesized that the limitations of the approaches discussed above could be overcome by integrating these two approaches, i.e., using miRNA array profiling as a "clinical/biological" filter to generate a restricted/selected miRNA expression library, which could then be used for functional genetic screening. To test our hypothesis, we generated a restricted miRNA expression library as follows: 1) We used array-based comparative genomic hybridization (aCGH) profiles as the "clinical/biological" filter. miRNAs that are highly amplified in human cancer were selected based on our previous aCGH studies (32) . In ovarian (n=109) and breast (n=73) cancer specimens, 55 and 166 miRNAs were identified, respectively, with DNA copy number amplification observed in >15% of cases ( Figure 1A ; Table S1 ). 2) These potential oncomirs were further concentrated by combining the miRNAs that were co-amplified in both ovarian and breast tumors (n=41) ( Figure 1B ; Table S1 ). 3) We used a whole genome human miRNA expression library (27) to derive this restricted library by selecting retrovirus miRNA expression vectors for these 41 miRNAs. This restricted library was used in an ovarian cancer cell line, 2008, to screen in vitro for miRNAs that are advantageous for cell growth in long-term culture. This was performed using a modification of a previously described whole genome-wide shRNA screening method (35, 36) ( Figure 1C) . Briefly, target cell populations were infected such that each cell contained, on average, a single integrated virus (27) . After 72 hrs, the cells were antibiotic-selected, then propagated for five weeks to expand those cell clones with a growth advantage, and seeded again at low density in 150 cm culture dishes to isolate single cell colonies. Large and aggressively growing single colonies were collected and expanded in 6-well plates. DNA was extracted from >100 colonies and virus insertions were amplified by PCR and confirmed by DNA sequencing ( Figure 1C ).
mir-30d regulates cancer cell proliferation, senescence, and apoptosis in vitro
Several potential candidate oncomirs, including mir-30d, were identified by the above approach. mir30d represented 42% of the viral insertions sequenced. To validate and further characterize this finding, we first transfected a chemically synthesized mir-30d mimic into six cancer cell lines including 2008 and five independent cancer cell lines. Using an MTT assay, we found that forced mir-30d expression significantly increased cell growth in all six cell lines ( Figure 2A ). Meanwhile, a similar experiment was performed using a lentiviral mir-30d inhibitor. Consistent with our gain-of-function studies, blocking of endogenous mir-30d expression even more remarkably decreased the growth rates of cancer cell lines in vitro ( Figure 2B ). In 2008, MDA-MB-231 and HCT116, mir-30d inhibitor nearly completely blocked cell growth ability in vitro ( Figure 2B ). In both mimic and inhibitor experiments, total RNA was isolated from parallel transfection wells, and real-time RT-PCR was used to confirm the effect on mir-30d expression.
Since blocking endogenous mir-30d significantly reduced tumor cell proliferation, we next examined the effect of mir-30d inhibitor treatment on the cell cycle, using DNA staining followed by flow cytometry.
We found that mir-30d inhibitor transfection led to a significant cell cycle arrest at the G 0 /G 1 phase ( Figure 2C ). Finally, we observed that transfection of a mir-30d inhibitor not only significantly blocked cancer cell proliferation ( Figure 2B ), but also remarkably increased the number of the cells with typical senescence morphology ( Figure 2D ). To confirm this observation, we examined ȕ-galactosidase activity, a known characteristic of senescent cells that is not found in presenescent, quiescent, or immortal cells. 6 days after transfection with a mir-30d inhibitor, the percentage of ȕ-galactosidase positive cancer cells was significantly increased compared to controls ( Figure 2E ).
Most recent studies have suggested that the mir-30 family regulates apoptosis in cardiomyocytes (37) and cancer cells (30) . It indicates that decreasing of cell death may be another mechanism to explain the advantage of mir-30d for cell growth in long-term culture (about two month selection in our genetic screening approach). Thus, we examined whether mir-30d regulated apoptosis in the cell lines used in this study. Based on a bioluminescent caspase assay, we found that transfection of a mir-30d mimic significantly reduced caspase-3 activity in camptothecin-induced apoptosis in cancer cells ( Figure 3A ).
This result was further confirmed via Western blot. Figure 3B shows that the transfection of a mir-30d mimic remarkably reduced both total and cleaved caspase-3 protein in both control and camptothecininduced apoptotic cells. To prove that mir-30d blocks chemotherapy drug induced apoptosis, the apoptotic status after camptothecin treatment was analyzed by flow cytometry using an Annexin-V assay and reporter expression vector was transfected into the MDA-MB-231 cells. We found that the tumors produced by cells in which mir-30d had been knocked-down displayed slow growth in vivo with the Matrigel mixture, consistent with the first experiment (without the Matrigel mixture). Thus, knockdown of mir-30d significantly decreases the growth rate of tumors in vivo ( Figure 4C to E, n=5, p<0.05). This in vivo result provides further evidence indicating that mir-30d is an oncomir in human cancer.
mir-30d exhibits a high frequency of genomic amplification in human solid tumors
Our previous aCGH study indicated that the DNA copy number of mir-30d was amplified in about 50% of the ovarian cancer (n=109) and 40% of the breast cancer (n=73) specimens (32) . First, we investigated whether there was a positive correlation between the DNA copy number amplification and mature mir-30d expression in primary tumors. We analyzed mature and pre mir-30d expression in 36 primary ovarian tumor specimens by real-time RT-PCR, and found that both mature and pre mir-30d expression was detectable in all specimens and significantly higher in the tumors with a high DNA copy number of mir-30d (n=21, mature mir-30d: p=0.014; pre-mir-30d: p<0.001) compared to tumors with no amplification of mir-30d DNA copy number (n=15). We also examined the 16 ovarian cancer cell lines.
The average level of mir-30d expression was higher in the cell lines with amplified mir-30d DNA copy numbers ( Figure 5A ). In addition, the average level of mir-30d expression in these ovarian cancer cell lines was remarkably higher than in immortalized human ovarian surface epithelial cells (IOSEs, Figure   5A ), which were used as control cells for epithelial ovarian cancer (38) . These results demonstrate that genomic copy number amplification of mir-30d increases mature mir-30d expression in human cancer.
Next, we asked whether mir-30d also exhibits high levels of genomic amplification in other human cancers. We analyzed a panel of high resolution DNA copy number profiling data sets that consisted of 1,282 primary tumors representing nine human cancer types (detailed information provided in the methods section and Table S2 ). We found that the genomic locus harboring mir-30d was significantly amplified in 8 of these 9 human cancers ( Figure 5B specimens revealed that the genomic locus harboring mir-30d was amplified to greater than five copies, and 30.4% of the specimens indicated that mir-30d was present in 3-5 copies ( Figure 5B ). Overall, mir30d was amplified at a high frequency (> 30%) in human solid tumors (n=1,282). In contrast, 2.7% of tumors displayed a heterozygous deletion for mir-30d, and one specimen with a homozygous deletion of mir-30d was found ( Figure 5B ). These DNA copy number profiling results were further validated using a single nucleotide polymorphism (SNP) array on six matching human tumor types (detailed information provided in the methods section). One hundred and ninety-two established tumor cell lines were examined in this SNP array. The genomic locus containing mir-30d was examined in each cell line ( Figure 5C ).
Consistent with the aCGH findings, mir-30d displayed remarkable amplification in tumor cell lines ( Figure 5B ). In breast cancer (n=29), in 6.9% of specimens the genomic locus harboring mir-30d was present in more than five copies, while 44.8% of the specimens had 3-5 copies ( Figure 5B ). Collectively, mir-30d was amplified in more than 30% of the cancer cell lines examined ( Figure 5B, n=192 ).
Higher levels of mir-30d expression were significantly correlated with poor clinical outcomes in ovarian cancer patients
To study the expression of mature mir-30d in human cancer, in situ hybridization (ISH) was performed on ovarian cancer tissue arrays (n=330). We detected mature mir-30d in the majority of ovarian cancer specimens (81.2%, 268/330, Figure 5D ). Strong cytoplasmic hybridization signal was mainly found in tumor islet but not stroma cells ( Figure 5D ). To further examine the clinical significance of mir-30d expression, the cytoplasmic ISH signals were scored as negative or weak positive (n=62), intermediate positive (n=161), and strong positive (n=107, Figure 5D ). We found that higher expression levels of mature mir-30d in ovarian cancer were significantly correlated with poor clinical outcomes in these patients ( Figure 5E 
mir-30d regulates a large number of transcripts/genes in cancer cells
Up to one-third of messenger RNAs (mRNAs) appear to be miRNA targets (33) . Each miRNA can target hundreds of mRNA transcripts (39) affecting the production of proteins (40, 41) , and more than one miRNA can converge on a single target transcript (42) . Taken together, the potential regulatory circuitry afforded by specific miRNAs may be enormous, although typically this repression is relatively mild (39) (40) (41) . Therefore, we believed that the oncomiric function of mir-30d would be mediated by repressing multiple signaling pathways rather than by targeting one or a few cancer-associated proteins. To test this hypothesis, we used microarray analyses to profile the transcriptional changes seen after the transfection of a mir-30d mimic into two cancer cell lines ( Figure 6 ). Consistent with other reports in the literature (39) (40) (41) , the repression of genome-wide transcription caused by mir-30d was typically relatively mild. We (Figure 6 B and D) . The three hexamers that were most overrepresented in the down-regulated genes were ACATTT, CATTTG and ATTTGT (p<10 -19 ) and corresponded to the seed positions of mir-30d ( Figures 6B and D) . We also predicted mir-30d targets using TargetScan (33) , and found that 128 of 462 and 151 of 376 down-regulated transcripts in 2008 and MDA-MB-231, respectively, were mir-30d predicated targets ( Figure 6E ). This bioinformatic evidence strongly suggests that a large percentage of those down-regulated transcripts were indeed directly repressed by mir-30d. That is, about 30-60% of the down-regulated transcripts were direct mir-30d targets. Additionally, about 1 of 3 (n=150) down-regulated transcripts were shared by both cell lines, and 79 of these were predicted to be mir-30d targets by TargetScan (Table S5) Figures 6F and Figure S2) . Notably, three of known mir-30d targets identified by another group, GNAI2 (44) and GALNT1, GALNT7 (45) were consistently found in our 79 transcript list ( Figure 6E ). Taken together, these results indicate that mir-30d represses a large number of transcripts, in cancer cells.
Most importantly, miRNA target predication programs strongly indicated that CASP3, a central protein in the execution-phase of cell apoptosis, was a potential target of mir-30d ( Figure 7A ). The mir30d binding sites in the CASP3 3ƍ-UTR predicated by TargetScan were broadly conserved among different species ( Figure 7A ). Additionally, we found that both protein and mRNA levels of CASP3were significantly repressed after transfection of mir-30d into cancer cells (protein: Figure 3B and mRNA: Figure 6E and 7B). Thus, we used a luciferase reporter assay to experimentally examine whether mir-30d directly regulated CASP3 expression via its 3ƍ-UTR. The seeding sequences of mir-30d in the CASP3 3ƍ-UTR were mutated, and overexpression of mir-30d was found to significantly reduce luciferase activity in the wild type but not the binding site mutant CASP3 3ƍ-UTR reporters ( Figure 7C ). These results demonstrate that mir-30d directly regulates expression of CASP3, a master regulator of apoptosis, in cancer cells. It is one of important molecular mechanisms to explain our observation on cellular function of mir-30d in apoptosis and long-term maintenance of tumor cell growth.
Discussion
In the present study, we report a novel, clinically guided, genetic screening approach to identify oncomirs in human cancer. This approach uses array-based profiling data as a clinical/biological filter to generate a selected functional genetic screening library. Our strategy can distinguish "causal" from CAN-11-2484 "bystander" genetic events to decrease noise and artificial results, and also requires less time and labor than whole-genome wide genetic screening approaches. With this novel strategy, one promising oncomir candidate, mir-30d, was successfully identified. This clinically guided genetic screening approach is a powerful tool to identify oncomirs as biomarkers for diagnosis or as targets for the development of cancer treatments. There are also limitations of our strategy to identify oncomirs. For example, only oncogenic miRNAs, especially miRNAs promoting tumor cell growth or survival, are able to be identified by our current approach. This limitation can be overcome by combining with other library screening approaches such as transwell assay (to identify miRNAs promoting migration and invasion), soft agar assay (to identify miRNAs inducing malignant transformation), and negative selection approaches (to identify tumor suppressor miRNAs). Finally, since our approach is based on an in vitro positive selection strategy, the oncomirs that give a growth advantage to tumor cells in vitro, such as promoting angiogenesis and regulating anti-tumor immune response, cannot be identified by our approach. Combination with an in vivo selection approach will more closely recapitulate the pathobiology of human cancers. mir-30d was initially identified using this screening approach, where the cells harboring miRNAs producing a growth advantage could be expanded in vitro. Subsequently, our in vitro experiments demonstrated that mir-30d regulates cell proliferation, senescence, and apoptosis. In agreement with our observations, Kumar et al. also reported that mir-30d inhibits apoptosis in human cancer via regulation of the p53 pathway (30) . A similar function of mir-30d was also observed in normal cells such as cardiomyocytes (37) . Furthermore, using a xenograft model, we showed that inhibition of endogenous mir-30d expression remarkably blocked tumor growth in vivo. Two independent groups have provided strong evidence indicating that mir-30d promotes tumor invasion and metastasis in hepatocellular carcinoma via regulating GNAI2 (44) and in melanoma via repressing GALNT7 (45) . Consistent with these studies, we also found that mir-30d repressed GNAI2 and GALNT7 expression in ovarian and breast cancer cell lines ( Figure 6E) , and using an in vitro migration assay, we observed that transfection of mir- Author Manuscript Published OnlineFirst on November 4, 2011; DOI: 10.1158/0008-5472. CAN-11-2484 study found that the DNA copy number of mir-30d was remarkably amplified (more than 30%) in 8 of 9 human cancer types that were examined. This suggests that mir-30d amplification in human cancer is a common oncogenic event. In agreement with our conclusion, two independent groups reported that mir30d was amplified in brain tumors (46) and melanoma (45) . Most importantly, we found that overexpression of mir-30d was significantly associated with a poor clinical outcome in human ovarian cancer patients. In addition, a recent genome-wide serum miRNA profiling study demonstrated that higher levels of serum mir-30d were significantly associated with shorter survival times in non-small cell lung cancer patients (47) . Gaziel-Sovran et al. also reported that higher levels of mir-30d expression was correlated with shorter time to recurrence and lower overall survival in melanoma (45) . Taken together, the above evidence strongly suggests that mir-30d serves as an oncomir in human cancer.
The results of this study indicate that mir-30d can down-regulate a large number of transcripts in human cancer cells, although as with most other miRNAs, this repression is relatively mild (39) (40) (41) . We identified 79 protein coding genes which were predicted by bioinformatics to be potential direct targets of mir-30d. We then showed that the expression of these genes (involved in multiple cancer-associated pathways such as apoptosis and migration) were indeed down-regulated by the transfection of a mir-30d mimic into each of the two cell lines used in our microarray study as well as two independent cancer cell lines. We found that CASP3, a central protein in the execution-phase of cell apoptosis, is a direct target of mir-30d. Another mir-30d targets (GNAI2 which was identified in liver cancer (44) ; GALNT1 and GALNT7 which were identified in melanoma (45)) were also found in our target list. Notably, we also found that a relatively large number of predicted mir-30d target genes ( A and B. The control and mir-30d knockdown tumors (MDA-MB-231) were injected sc (without MatriGel) into female nude mice (n=5). Tumor growth rates were measured and followed up for 38 days after tumor cell injection. C. The control and mir-30d knockdown tumors (MDA-MB-231) were injected sc (with MatriGel) into female nude mice (n=5). Tumor growth rates were measured and followed up for 38 days after tumor cell injection. D. The xenograft tumors (with MatriGel) were monitored using a bioluminescence optical imaging system at day 38 post injection. Right: control; left: mir-30d inhibitor.
E. Quantitative data of the optical imaging shown as photons (p) per second. * p<0.05 Rno, Rat; Cpo, Pig; Sar, Shrew; Cfa, Dog; Fca: Cat; Eca, Horse; Bta, Cow; Dno, armadillo; Laf, elephant.
B.
The mir-30d mimics and control mimic were transiently transfected into four cancer cell lines. At 48 hrs post-transfection, total RNA were collected, and the endogenous CASP3 expression was examined by real-time RT-PCR. C. Reporter assays using wild type and mir-30d binding site mutant CASP-3 3ƍ UTR.
The mir-30d mimic transfection significantly reduced luciferase activity in the wild type but not the binding site mutant CASP3 3ƍ UTR reporters. * P<0.05; ** P<0.01
